2013


To access this material please log in or register

Register Authorize
2013/№6

Effect of trimetazidine on cumulative survival rate in patients with ischemic heart disease complicated by chronic heart failure

Ilyukhin O. V., Tarasov D. L., Ilyukhina M. V., Temirsultanova T. Kh., Kalganova E. L., Lopatin Yu. M.

Keywords: patients’ survival, coronary heart disease, treatment, trimetazidine, CHF

DOI: 10.18087/rhj.2013.6.1901

Background. Myocardial cytoprotectors, including trimetazidine, are extensively used for treatment of many cardiovascular diseases. However sufficient data supporting the effect of metabolic therapy on long-term prognosis are not available. Aim. Evaluating the cumulative survival rate in patients with stable IHD complicated by CHF during the treatment with trimetazidine modified release. Materials and methods. Study patients were divided into the following groups: 66 patients constantly received trimetazidine in addition to their current therapy and 53 patients were included in the control group. The groups were comparable by major studied clinical morpho-functional parameters of the heart. Cumulative survival rate was evaluated using the Kaplan-Meier method. Results. Follow-up duration was 1 to 72 months. Six-year cumulative survival was considerably different in the study groups. At the end of study, the survival rate was 0.848 vs. 0.698 for the trimetazidine treatment group and the control group, respectively (p=0.044). Relative risk (RR) reached 0.51 at 95 % CI 0.25–0.92 (p<0.05). All cases of death, non-fatal infarction and stroke for the entire observation period were used as a combined index. Kaplan-Meier curves significantly diverged already by 30 months of observation, when the difference between groups was 13.3 % in favor of the trimetazidine group. Six-year survival was 15.7 % longer (p=0.033) in the group of patients receiving trimetazidine together with the standard therapy. RR was reduced to 0.61 at 95 CI 0.97–0.35 (p<0.05). Conclusion. The trimetazidine treatment added to the traditional anti-anginal therapy results in a significant increase in cumulative 6year survival and a decrease in cardiovascular outcomes in patients with IHD complicated by CHF.
  1. Ситникова М. Ю., Лелявина Т. А., Шляхто Е. В. и др. Особенности клиники, диагностики и прогноза хронической сердечной недостаточности у госпитализированных пациентов старческого возраста. Журнал Сердечная Недостаточность. 2006;7 (2):85–87.
  2. Агеев Ф. Т., Даниелян М. О., Мареев В. Ю., Беленков Ю. Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА–О–ХСН). Журнал Сердечная Недостаточность. 2004;5 (1):4–7.
  3. Stewart S. Prognosis of patients with heart failure compared with common types of cancer. Heart Fail Monit. 2003;3 (3):87–94.
  4. Kim J. Effect of trimetazidine therapy in AMI patients: from Korean Acute Miocardial Infarction registry (KAMIR). WCC-12‑ABS-1621.
  5. Di Napoli P, Di Giovanni P, Gaeta MA et al. Trimetazidine and reduction in mortality and hospitalization in patients with ischаemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol. 2007;50 (5):585–589.
  6. Lopatin YM, Ilyukhin OV, Ilyukhina MV et al. Long-term trimetazidine modified release therapy improves prognosis in post-myocardial infarction patients with angina pectoris and heart failure. Eur Heart J. 2012;33 (Abstract Suppl): 346–347.
  7. Согласованное мнение экспертов о целесообразности использования миокардиального цитопротектора триметазидина (Предуктала МВ) в комплексной терапии больных с хроническими формами ишемической болезни сердца. Современные медицинские технологи. 2012;9:52–53.
  8. Диагностика и лечение стабильной стенокардии. В кн. Нацио­нальные клинические рекомендации. – М.: Меди ЭКСПО, 2009. –с. 332–382.
  9. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischae­mic heart disease, a novel approach to treatment. Eur Heart J. 2004;25 (8):634–641.
  10. Карпов Ю. А., Шальнова С. А. Деев А. Д. Результаты клинического этапа национальной программы ПРЕМЬРА. Прогресс в кардиологии. 2006;2:12–16.
  11. Васюк Ю. А., Шальнова С. А., Куликов К. Г., Школьник Е. Л. Исследование ПРИМА: триметазидин с модифицированным высвобождением действующего вещества в лечении пациентов со стабильной стенокардией, перенесших инфаркт миокарда. Эпидемиологический и клинический этапы. Кардиология, 2008;48 (12):10–13.
  12. Effect of 48‑h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project--Free Radicals. Eur Heart J. 2000;21 (18):1537–1546.
  13. Polonski L, Dec I, Wojnar R, Wilczek K. Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty. Curr Med Res Opin. 2002;18 (7):389–396.
  14. Tunerir B, Colak O, Alatas O et al. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg. 1999;68 (6):2173–2176.
  15. Fabiani JN, Ponzio O, Emerit I et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino). 1992;33 (4):486–491.
  16. Di Napoli P, Taccardi AA, Barsotti A. Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005;91 (2):161–165.
  17. Belardinelli R, Cianci G, Gigli M et al. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol. 2008;51 (6):611–615.
  18. Илюхин О. В., Тарасов Д. Л., Пром А. К. и др. Сравнительная оценка эластических свойств магистральных артерий у больных стабильной стенокардией на фоне метаболической терапии. Российский кардиологический журнал. 2012;1 (93):24–30.
  19. Инжутова А. И., Быкова В. В., Новикова Т. В. и др. Улучшение функции эндотелия цитопротектором триметазидин при эссенциальной и ятрогенной артериальной гипертензии, вызванной сунитинибом. Вестник науки Сибири. 2012;4 (3):291–306.
  20. Iyengar SS, Rosano GM. Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: a preliminary study (METRO). Am J Cardiovasc Drugs. 2009;9 (5):293–297.
  21. Gao D, Ning N, Niu X et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97 (4):278–286.
Ilyukhin O. V., Tarasov D. L., Ilyukhina M. V. et al. Effect of trimetazidine on cumulative survival rate in patients with ischemic heart disease complicated by chronic heart failure. Russian Heart Journal. 2013;12(6):355-359

To access this material please log in or register

Register Authorize
Ru En